about
The CD47 pathway is deregulated in human immune thrombocytopenia.Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency.Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study.Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantationBacterial Blood Stream Infections Negatively Impact on Outcome of Patients Treated with Allogeneic Stem Cell Transplantation: 6 Years Single-Centre ExperienceRisk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric studyClinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence?Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and SplenomegalyA case report of acute myeloid leukemia and neurofibromatosis 1.Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature.Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsCirculating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopeniaRuxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallengePlatelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosisImpact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective studyDurability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patientsDifferences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a larBleeding in essential thrombocythaemia: a retrospective analysis on 565 patientsVery elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 yearsComparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years
P50
Q33393546-D084ABA8-AF0A-4684-BAB3-EDF813F5D938Q33402505-E834F42B-213A-4A05-B1B9-FBECE5519F5DQ33403052-7DC84090-ED7E-4183-8FAD-9F139484CC29Q33404320-929B6632-F528-452A-BBE2-8E645DA5B374Q33415996-D8422CEA-3ECD-4B09-AC52-8C3401E5604EQ33416947-23BCE829-73CE-4FA5-B78C-2B3C89FA6D5CQ33429426-E90EEC58-DBBF-483E-B0AE-9FF3DEF94907Q33437682-830EA425-0A8A-44B2-B205-47D14D9F5B4CQ33441917-CACB4FB0-4FED-4EA4-AC01-E94B04199CBAQ33554385-88AAF71C-6AC1-4438-9331-1D752324EA95Q33877932-D2D21EB6-8B67-44E6-A1AC-6C01477AD6FAQ38814941-0EAA05AD-1980-42CE-872E-84DC2B5660ECQ38830536-985EB2BC-1C54-445A-8EE7-00B96E6AEADFQ39207319-3A46C504-FE4C-4A54-84A5-2CB15F7766C6Q39986585-AE955BD1-F958-4E55-9BE7-5DB49469AA05Q40125614-DA079061-1DBC-4785-9302-BCBE5CC7E8F8Q40564541-89329560-9397-4D4A-88ED-4F6925C79D96Q43080898-792F5ACE-9253-476B-B1DC-8FED62419446Q44217288-DD68821D-3FEC-4D8F-8649-3625F2AAB143Q45236578-BAB3CD98-9AAC-4ADF-AC4E-DCF081278E18Q45912397-12039AC3-9279-42E4-85F5-F2E699FE40B6Q46113435-84A72A76-A7E0-4510-A6AB-52F8A22583D9Q46126059-A48829A9-93E3-4C67-8C7A-EAD192A134BCQ47824825-603E1F9E-5EC3-4EE3-A48C-C74C0945DAACQ48138032-6D22DB2D-0429-4E27-8885-7F6DF927ADC0Q50352928-1408560E-2703-44A1-BE3C-36384F293852Q50546494-01D3CD65-CBEA-4DFC-A6D5-7A5F01C6C8F9Q52721155-150D5DFA-F26B-49E0-9BC4-2B2D4C9DAB35Q54282700-F0BB28B3-01D7-482C-A85A-2EA349850134Q54329508-B1FE8F36-A067-4846-B3CB-D896821CBD77Q56365273-E3D386E8-429B-445A-96FB-A18C0BF8DE5FQ56969429-79AE962D-0D61-4853-A8AC-F8D9FCA2B4C5Q56970836-E21B3AB2-A3DC-49E6-8280-B91346360BA8Q56971079-BA9E1653-E185-47E1-AE2A-87A42F45BE05Q56984881-7E597700-DDB3-42BF-AAB0-08DCB72C5D16Q58448895-296D3FA5-445A-4CFF-A6B5-874935461AE0Q58448907-51AFA890-B769-4D3A-BD9F-8C0DA1CC44EFQ84971538-2ADE4440-D574-417D-849D-B0B19A2EB9F8Q85058160-67D7A006-862A-48D8-BBB0-1D915E2DE3F8Q88023366-EEB9ACC0-F7A6-497B-8A42-796596F43E3A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Polverelli
@ast
Nicola Polverelli
@en
Nicola Polverelli
@es
Nicola Polverelli
@nl
Nicola Polverelli
@sl
type
label
Nicola Polverelli
@ast
Nicola Polverelli
@en
Nicola Polverelli
@es
Nicola Polverelli
@nl
Nicola Polverelli
@sl
prefLabel
Nicola Polverelli
@ast
Nicola Polverelli
@en
Nicola Polverelli
@es
Nicola Polverelli
@nl
Nicola Polverelli
@sl
P106
P1153
26039392800
P21
P31
P496
0000-0001-6297-9697